FDA Approves Zanubrutinib for CLL or SLL

Recommended

FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021

FDA Approves Updated Drug Labeling for Capecitabine Tablets Under Project Renewal

FDA Approves New Dosing Regimen for Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn

Adcetris Approved for Pediatric Patients With High Risk Classical Hodgkin Lymphoma

FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC

FDA Approves Teclistamab for Patients With Relapsed/Refractory MM

FDA Approves New Immunotherapy Combo for Liver Cancer

FDA Approves Zanubrutinib for CLL or SLL

header-info

Jan, 23, 2023

On January 19, the US Food and Drug Administration (FDA) approved the kinase inhibitor zanubrutinib (Brukinsa) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).